Key result
No clinical data is available in the provided text, which consists only of the journal's editorial board information.
Why the study?
Does Solulin demonstrate safety, tolerability, and predictable pharmacokinetics and pharmacodynamics compared to placebo in healthy volunteers?
Population
42 healthy volunteers (30 in single ascending dose group, 12 in multiple ascending dose group)
Comparison
Solulin via single or multiple ascending… vs Placebo
Design
Other
Authors
Loading...
No clinical data available on Solulin; leaves open its safety and development as anticoagulant.
Does Solulin demonstrate safety, tolerability, and predictable pharmacokinetics and pharmacodynamics compared to placebo in healthy volunteers?
In this first-in-human Phase I study, the novel thrombomodulin analogue Solulin showed a favorable safety profile and predictable pharmacodynamics, supporting its further investigation as an anticoagulant.
Iersel et al. (2010) studied this question. Solulin was evaluated. No clinical data is available in the provided text, which consists only of the journal's editorial board information.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: